Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price was up 35.7% during trading on Tuesday . The company traded as high as C$0.10 and last traded at C$0.10. Approximately 256,639 shares were traded during trading, an increase of 172% from the average daily volume of 94,340 shares. The stock had previously closed at C$0.07.
Hemostemix Stock Performance
The firm has a market capitalization of C$10.45 million, a P/E ratio of -6.00 and a beta of 0.20. The firm has a 50 day moving average price of C$0.08 and a two-hundred day moving average price of C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- How to Use the MarketBeat Excel Dividend Calculator
- 3 Stocks Helping to Bring AI to Healthcare
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- What is a SEC Filing?
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
